http://www.biospace.comBioSpace RSS GeneratorSat, 25 May 2013 16:36:11 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2011http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/12/audeo-oncology-alchemia-orbis-aurx.html?ana=otjAn Australian import to San Francisco plans to raise $49 million in an initial public offering to fuel late-stage development of its experimental cancer-targeting drug. Audeo Oncology Inc., incorporated in June as part of a reorganization of the publicly traded Australian company Alchemia Ltd., priced its IPO of 3.25 million shares at $14-16 per share. It will trade starting next week on the NASDAQ...Mon, 10 Dec 2012 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=277343&full=125 October 2012 -- A French biotech company supported by funds raised through a scheme the BIA has proposed is introduced in the UK, has announced the raising of 14.2 million in its Initial Public Offering (IPO) on the Euronext. </p><p>Funds raised through the Fonds Commun de Placement dans I'Innovation (FCPI), on which the BIA has modelled its Citizens' Innovation Funds proposal launched last...Thu, 25 Oct 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20121005by Richard Daverman, PhD</p><p>October 5, 2012 -- Fosun Pharmas long-in-the-works IPO on the Hong Kong exchange is scheduled to take place this month, raising a diminished $600 million. The company received regulatory approval for the offering five months ago, but market conditions have held the transaction back until now and caused the company to drop the projected take from $800 million. There...Fri, 05 Oct 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120906_1by Richard Daverman, PhD</p><p>September 6, 2012 -- China National Biotec Group, a unit of China's sprawling state-owned pharmaceutical giant, Sinopharm Group, will seek to raise up to 10 billion RMB ($1.6 billion) in a Hong Kong IPO. The company was given an OK to stage its previously announced IPO by Hong Kongs environment ministry today. It still needs the blessing of the China Securities Regulatory...Thu, 06 Sep 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120818by Richard Daverman, PhD</p><p>August 18, 2012 -- Hangzhou Tigermed Consulting, a clinical-stage CRO, staged an $80 million IPO on Shenzhens ChiNext exchange; Hainan Shuangcheng Pharma made its public company debut on the Shenzhen main board, raising $94 million; two China medical research organizations will work with the National University of Ireland Galway to develop polymer delivery systems...Tue, 21 Aug 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120817_1by Richard Daverman, PhD</p><p>August 17, 2012 -- Hangzhou Tigermed Consulting Co., a clinical-stage CRO, staged its IPO today on Shenzhens ChiNext exchange. The IPO, which constitutes 25% of the companys outstanding stock, placed 13.40 million shares in investors hands at a price of 37.88 RMB, a price/earnings ratio of 44. The transaction raised 508 million RMB ($80 million) for the company...Mon, 20 Aug 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120815by Richard Daverman, PhD</p><p>August 15, 2012 -- Hainan Shuangcheng Pharmaceuticals debuted on the Shenzhen exchange last week, raising 600 million RMB ($94 million) in its IPO offering. Founded in 2000, Hainan Shuangcheng Pharma is a high-tech enterprise specializing in chemosynthetic polypeptide medicines. The offering was priced at 20 RMB, and the companys shares have moved up to 25.2 RMB...Wed, 15 Aug 2012 12:00:00 AM GMThttp://www.marketwatch.com/story/cathay-industrial-biotech-withdraws-ipo-plans-2012-06-11Cathay Industrial Biotech, a Chinese producer of biobutanol and LCDAs used in chemical and fuel markets, withdrew its plans for an initial public offering on Monday. The Shanghai, China-based company, which was founded in 1997, originally postponed its IPO in August 2011. The company was planning on raising $90 million by offering 6.9 million shares at a price range of $12 to $14. Morgan Stanley, Deutsche...Wed, 13 Jun 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120518_1by Richard Daverman, PhD</p><p>May 18, 2012 -- China National Biotech Group (CNBG) expects to raise up to 10 billion RMB ($1.6 billion) in a Hong Kong IPO, according to sources. CNBH is one of many subsidiaries of the sprawling state-owned China National Pharmaceutical Group Corp (Sinopharm). Last November, Zhiping Song, Chairman of the parent company, said the IPO would take place in the first...Fri, 18 May 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120411April 11, 2012 --Shanghai Fosun Pharma has been given regulatory approval to issue 547 million H shares in a Hong Kong IPO. The transaction is expected to occur in the second quarter. Because the company's Shanghai stock price has slipped lower in the last six months, the offering has also dropped in size from the original announcement: it is now expected in a range between $600 million and $800 million...Thu, 12 Apr 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120216February 16, 2012 -- Beijing Leadman Biochemistry completed an IPO on the Shenzhens ChiNext exchange, raising almost 500 million RMB ($79 million). The company issued 38.4 million shares at a price of 13 RMB. Leadman produces IVD reagents, medical devices, and chemical raw materials. The issue price reflects a PE ratio of 37. In its first open market session, Leadman rose even higher, climbing 2...Thu, 16 Feb 2012 12:00:00 AM GMThttp://www.pharmalot.com/2012/02/chinese-drugmaker-ipo-protested-over-bear-bile/Just as major drugmakers such as GlaxoSmithKline express more interest in traditional Chinese medicine (see this), some practices are generating sustained protests. One example is using bile from captive black bears to make pharmaceuticals for treating the liver and eyes. To thwart Guizhentang Pharmaceuticals, which reportedly keeps nearly 500 bears on its farms, from trading its stock publicly, animal...Mon, 13 Feb 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20120117January 17, 2012 -- Xizang Haisco Pharmaceutical Group, which produces TCM drug formulations and active pharmaceutical ingredients, completed a $127 million IPO on Shenzhens Small and Medium-Sized Enterprises Board. The company, located in Chinas autonomous Tibet region, is the 11th Tibetan entity to become publicly owned. CITIC Securities was the lead underwriter. More details....</p><p>Stock...Tue, 17 Jan 2012 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20111109November 8, 2011 -- China National Biotechnology Group (CNBG) will raise as much as $2 billion in a Hong Kong IPO, an event that is expected to take place in the first half of next year. China National Biotech is the largest biotechnology company in China, producing a long list of vaccines and blood products. Reportedly, the company will change its name to China Biotechnology Co. China Biotech is a...Wed, 09 Nov 2011 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20110728_1July 28, 2011 -- Shares of Shijiazhuang Yiling Pharmaceutical climbed 27% following the companys IPO on the ChiNext exchange. As we reported last week, the company, which makes cardiovascular and cerebrovascular medicines, bumped the price of its IPO higher by one-third due to higher-than-expected demand, raising the value of the transaction to 2.25 billion RMB ($348 million). Even after the price...Thu, 28 Jul 2011 12:00:00 AM GMThttp://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/8378101/HIV-drug-firm-Koronis-Pharmaceuticals-eyes-London-listing.htmlLONDON, March 13 (Reuters) - Koronis Pharmaceuticals, a privately held U.S. biotech firm working on a new kind of HIV drug, is looking to list in London later this year or early in 2012, its chief executive said. Mon, 14 Mar 2011 12:00:00 AM GMTttp://www.chinabiotoday.com/articles/20101004October 4, 2010 -- ShangPharma Corp., the Shanghai-based CRO, announced plans to stage a $90 million IPO on the New York Stock Exchange. Founded in 2003, the company is one of the largest CROs in China with a staff of more than 1,600 scientists. One of its six divisions, Shanghai ChemPartner, is devoted exclusively to projects from Eli Lilly Company. More details....Tue, 05 Oct 2010 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20100914September 14, 2010 -- Yunnan Walvax Biotechnology, a company that specializes in human vaccines, will IPO on the Shenzhen ChiNext Exchange. Although most financial details were not released, the company did say it would issue 25 million new shares, bringing its share count up to 100 million. More details....Tue, 14 Sep 2010 12:00:00 AM GMThttp://www.chinabiotoday.com/articles/20100724July 24, 2010 -- China life science IPOs raised $5.4 billion in the last 12 months, led by the $1.3 billion IPO of Sinopharm Group; Chinas central government spent $11.8 billion on healthcare reform in the first half of 2010; CCBI Healthcare Fund made an investment in Shanghai Kindly Enterprise Development Group; Lijun International Pharmaceutical set up a Joint Venture with Tonghua Dongbao Pharma...Mon, 26 Jul 2010 12:00:00 AM GMT